Answers are grounded in this paper and cite their sources.
Introduction . According to the WHO, the number of children aged 1 to 15 years infected with hepatitis C virus worldwide is approximately 3.2 million. The introduction of direct-acting antiviral drugs (DAAs) has radically changed the approach to treatment. Given the duration of the disease and changes in the metabolic and nutritional status of patients, changes in growth rates and weight gain can be observed. А im. To assess the dynamics of mass and growth indicators and body mass index (BMI) in children with chronic hepatitis C (CHC) before and after direct-acting antiviral therapy. Materials and methods . At the first stage, a single-center non-randomized study included 41 full-term children with CHC who realized perinatal contact. After excluding 7 patients, the final cohort was 34 children who received DAAs (glecaprevir 100 mg and pibrentasvir 40 mg) for 8 to 12 weeks. Anthropometric parameters (height, weight, BMI) were analyzed according to the data at the time of birth, as well as 6 months before and 6 months after a stable virological response. Results. Baseline anthropometric measures at the moment of birth were consistent with healthy full-term infants. Before the initiation of therapy, BMI values were within the normal range (BMI SDS from -1.0 to +1.0) in 76.4% of children, undernutrition (BMI SDS from -1.0 to -2.0) was observed in 8.8%, and overweight (BMI SDS from +1.0 to +2.0) was identified in 14.8% of patients. At 6 weeks after achieving sustained virological response, normal BMI SDS values were recorded in 82.4% of children, while undernutrition was observed in 5.9% and overweight in 11.7% of patients. Pre-treatment and post-treatment weight changes were statistically significant (p = 0.016). Conclusion . Mass and growth indicators in children with vertically acquired CHC did not differ from those of conditionally healthy peers at all stages of follow-up. Direct-acting antiviral therapy had no adverse effect on patients’ physical development.
No takes yet. Share an insight, caveat, or question.
Pervishko et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: